← Leaderboards
Frances L Johnson
Viewpoint Molecular Targeting, Inc.
$2,780,400
Attributed
$2,780,400
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2015–20$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,780,400 · 4
By mechanism
R44$1,982,028 · 1
R43$798,372 · 3
Top collaborators
No co-investigators on record.
Most similar at Viewpoint Molecular Targeting, Inc.
Same institution · by research overlap
- Michael King Schultz$7,092,453
- Michael Schultz$298,184
Others in their field
Top investigators on “Published Comment”
- David Allen · Integrated Laboratory Systems, Llc$46,406,745
- Robert Daniel Toto · University Of Texas Sw Med Ctr/Dallas$39,349,638
- Julianne L Imperato-McGinley · Weill Medical College Of Cornell Univ$37,304,492
- David Heimbrook · Leidos Biomedical Research, Inc.$21,781,988
- Kevin J Anstrom · Univ Of North Carolina Chapel Hill$18,999,509
- Benjamin G. Neel · New York University School Of Medicine$14,272,282
Research focus
Published CommentMetastatic MelanomaDoseTumorRadionuclide TherapyBaseMelanomaIowaMalignant NeoplasmsIncidenceRadiolabeledEffectivenessParticle TherapyPeptidesLeadMedical ImagingProductionClinical TrialsImproved OutcomeDesignImageDosimetryMeetingsPre-Clinical
Grant awards (6)
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$1,023,920
R44 · FY2020 · CA · contact PI
Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma$958,108
R44 · FY2019 · CA · contact PI
Receptor-targeted radionuclide therapy combined with immunotherapies to improve metastatic melanoma tumor response.$300,000
R43 · FY2019 · CA · contact PI
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$50,000
R43 · FY2017 · CA · contact PI
Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals$298,530
R43 · FY2016 · CA · contact PI
Image guided therapy for metastatic melanoma$149,842
R43 · FY2015 · CA · contact PI